LWAC
MRNA icon

Laurel Wealth Advisors (California)’s Moderna MRNA Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$309K Sell
1,723
-151
-8% -$24.7K 0.03% 499
2022
Q3 		$222K Sell
1,874
-19
-1% -$2.88K 0.02% 581
2022
Q2 		$270K Sell
1,893
-562
-23% -$80.3K 0.03% 524
2022
Q1 		$423K Sell
2,455
-14
-0.6% -$2.36K 0.04% 463
2021
Q4 		$627K Buy
2,469
+530
+27% +$155K 0.05% 377
2021
Q3 		$746K Buy
1,939
+12
+0.6% +$4.43K 0.14% 178
2021
Q2 		$453K Buy
+1,927
New +$344K 0.06% 297

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurel Wealth Advisors (California)'s MRNA Position: Q4 2022 in Review

Laurel Wealth Advisors (California) reduced its Moderna (MRNA) stake by 8.1% in Q4 2022, selling an estimated $24.7K and leaving 1,723 shares worth $309K. The position accounts for 0.03% of the portfolio, ranked #499.

Laurel Wealth Advisors (California) first reported a position in MRNA in Q2 2021 and has held it in 7 quarters since. The position peaked at $746K in Q3 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Laurel Wealth Advisors (California) held 1,723 shares of Moderna worth $309K as of Q4 2022.
  • Laurel Wealth Advisors (California) sold 151 Moderna shares in Q4 2022, an estimated $24.7K.
  • Moderna made up 0.03% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #499 holding.
  • Laurel Wealth Advisors (California) first reported a position in Moderna in Q2 2021 and has held it in 7 quarters since.
  • Laurel Wealth Advisors (California)'s Moderna position peaked at $746K in Q3 2021.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.